Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study

In the Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors (BENEFIT‐EXT), extended criteria donor kidney recipients were randomized to receive belatacept‐based (more intense [MI] or less intense [LI]) or cyclosporine‐based immunosuppr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Transplant
Hlavní autoři: Durrbach, A., Pestana, J. M., Florman, S., del Carmen Rial, M., Rostaing, L., Kuypers, D., Matas, A., Wekerle, T., Polinsky, M., Meier‐Kriesche, H. U., Munier, S., Grinyó, J. M.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5516151/
https://ncbi.nlm.nih.gov/pubmed/27130868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.13830
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky